Citigroup
APGE

Citigroup’s Apogee Therapeutics APGE Stock Holding History

Citigroup’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.4M Buy
289,464
+275,476
+1,969% +$24.8M 0.01% 853
2026
Q1 		$1.18M Buy
13,988
+5,106
+57% +$371K ﹤0.01% 3007
2025
Q4 		$670K Buy
8,882
+2,378
+37% +$150K ﹤0.01% 3398
2025
Q3 		$258K Sell
6,504
-16,424
-72% -$627K ﹤0.01% 3885
2025
Q2 		$996K Sell
22,928
-38,434
-63% -$1.46M ﹤0.01% 3197
2025
Q1 		$2.29M Buy
61,362
+5,260
+9% +$203K ﹤0.01% 2573
2024
Q4 		$2.54M Buy
56,102
+27,968
+99% +$1.43M ﹤0.01% 2614
2024
Q3 		$1.65M Buy
28,134
+10,023
+55% +$480K ﹤0.01% 2830
2024
Q2 		$713K Sell
18,111
-74,995
-81% -$3.64M ﹤0.01% 3151
2024
Q1 		$6.19M Buy
93,106
+89,337
+2,370% +$3.9M ﹤0.01% 1559
2023
Q4 		$105K Buy
+3,769
New +$75.6K ﹤0.01% 4184

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Citigroup's APGE Position: Q2 2026 in Review

Citigroup increased its Apogee Therapeutics (APGE) stake by 1,969% in Q2 2026, buying an estimated $24.8M and bringing the position to 289,464 shares worth $38.4M. The position accounts for 0.01% of the portfolio, ranked #853.

Citigroup first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Citigroup held 289,464 shares of Apogee Therapeutics worth $38.4M as of Q2 2026.
  • Citigroup bought 275,476 Apogee Therapeutics shares in Q2 2026, an estimated $24.8M.
  • Apogee Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #853 holding.
  • Citigroup first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.